← Browse by Condition
Medical Condition

muscle invasive bladder carcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for muscle invasive bladder carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — muscle invasive bladder carcinoma Clinical Trials

How many clinical trials are currently recruiting for muscle invasive bladder carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for muscle invasive bladder carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for muscle invasive bladder carcinoma?
muscle invasive bladder carcinoma research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a muscle invasive bladder carcinoma clinical trial?
Eligibility criteria for muscle invasive bladder carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
IRCCS San Raffaele 1 trial
Columbia University 1 trial
University of Florence 1 trial
Shilpa Gupta, MD 1 trial

Recruiting Clinical Trials

NCT06170177
Recruiting
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Enrollment
4,000 pts
Location
Italy
Sponsor
IRCCS San Raffaele
View Trial →
NCT06571708 Phase 2
Recruiting
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
Enrollment
36 pts
Location
United States
Sponsor
Columbia University
View Trial →
NCT04900558
Recruiting
Robotic Radical Cystectomy Outcomes
Enrollment
500 pts
Location
Italy
Sponsor
University of Florence
View Trial →
NCT05833867 Phase 1
Recruiting
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Enrollment
20 pts
Location
United States
Sponsor
Shilpa Gupta, MD
View Trial →

Related Conditions

bladder cancer (3) muscle invasive bladder urothelial carcinoma (1) bladder cancer tnm staging (1) bladder cancer stage iia (1) bladder cancer stage iib (1) bladder cancer stage iv (1) bladder leiomyosarcoma (1) bladder cancer stage ii (1) bladder cancer stage iiia (1) bladder cancer stage iiib (1) bladder cancer stage iiic (1) bladder urothelial carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology